Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 70.29% | 159.82% | 94.38% | 55.26% | -55.41% |
| Total Depreciation and Amortization | 11.12% | -50.11% | -6.67% | 90.00% | 1,476.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.18% | -1,064.21% | -82.62% | 13.57% | 625.60% |
| Change in Net Operating Assets | 94.30% | 53.78% | 600.00% | -152.23% | -1,304.98% |
| Cash from Operations | 43.52% | -14.66% | 112.64% | -12.70% | 36.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 526.34% | 100.00% | 100.00% | -90.27% |
| Total Debt Repaid | -- | 5.09% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -96.79% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -92.44% | -100.00% | -100.00% | -- | -- |
| Cash from Financing | -53.60% | 1,414.32% | -108.78% | 2,848.42% | -58.12% |
| Foreign Exchange rate Adjustments | 126.05% | 103.67% | -99.48% | -28.86% | 91.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.28% | 123.23% | -92.84% | 107.98% | -114.44% |